Philip Mark Hogarth

Philip Mark Hogarth

Auto-generated profile, based on publicly available information

Philip Mark Hogarth

Burnet Institute

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994
Verified
Book Chapter
Closed access
MHMark Hulett
Mark Hulett
PHP. Mark Hogarth
P. Mark Hogarth

30 March 2012 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PHP. Mark Hogarth
P. Mark Hogarth
GPGeoffrey A. Pietersz
Geoffrey A. Pietersz

1 May 1981 in Journal of Experimental Medicine
Verified
Journal Article
Open access
BLB E Loveland
B E Loveland
PHP M Hogarth
P M Hogarth
RRhodri Ceredig
Rhodri Ceredig
IMI F McKenzie
I F McKenzie
The Ly phenotype of cells mediating skin graft rejection was determined using monoclonal anti-Lyt-1.1 and Lyt-2.1 antibodies in CBA mice that received CBA lymphoid cells from mice sensitized to C57BL/6; i.e., alloantigenic differences arising from the H-2 and non-H-2 loci. It was clear that graft rejection was due wholly to the presence of Lyt-1 cells in the inoculum and that Lyt-123 or Lyt-23 cells had no effect. Furthermore, no synergism was noted between Lyt-1 and Lyt-2 cells. In this model, both the cytotoxic T cell and cytotoxic lymphocyte precursors were shown to be Lyt-123 and these could be depleted from sensitized Lyt-1 populations that mediated graft rejection. Thus cytotoxic T cells are not responsible for skin graft rejection, but rather, this is mediated by an Lyt-1 cell. Whether this T cell is distinct from other Lyt-1 cells (T helper, T cells mediating delayed hypersensitivity) is not clear at present, but other evidence, and traditional concepts, link graft rejection and delayed type hypersensitivity as being different manifestations of the same mechanism.

1 March 2002 in Immunity
Verified
Journal Article
Closed access
NBNadine Barnes
Nadine Barnes
AGAmanda L Gavin
Amanda L Gavin
PTPeck Szee Tan
Peck Szee Tan
PMPatricia Mottram
Patricia Mottram
FKFrank Koentgen
Frank Koentgen
PHP.MArk Hogarth
P.MArk Hogarth

19 March 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JAJessica C. Anania
Jessica C. Anania
ACAlicia Chenoweth
Alicia Chenoweth
BWBruce D. Wines
Bruce D. Wines
PHP. Mark Hogarth
P. Mark Hogarth
FcγRs have been the focus of extensive research due to their key role linking innate and humoral immunity and their implication in both inflammatory and infectious disease. Within the human FcγR family FcγRII (activatory FcγRIIa and FcγRIIc, and inhibitory FcγRIIb) are unique in their ability to signal independent of the common γ chain. Through improved understanding of the structure of these receptors and how this affects their function we may be able to better understand how to target FcγR specific immune activation or inhibition, which will facilitate in the development of therapeutic monoclonal antibodies in patients where FcγRII activity may be desirable for efficacy. This review is focused on roles of the human FcγRII family members and their link to immunoregulation in healthy individuals and infection, autoimmunity and cancer.

1 May 1999 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PHP. Mark Hogarth
P. Mark Hogarth
KMKelly F. Maxwell
Kelly F. Maxwell
MPMaree S. Powell
Maree S. Powell
MHMark Hulett
Mark Hulett
PBPeter A. Barton
Peter A. Barton
TGThomas P.J. Garrett
Thomas P.J. Garrett